2023年4月28日

除了後來憐憫BioAnalytics: Myla Lai-Goldman Myla Lai-Goldman被任命為董事會慈愛BioAnalytics公司發展中細胞外vesicle-based液體活檢對早期癌症檢測測試。最近,她被執行副總裁以及首席醫療和美國實驗室公司首席科學官在她工作超過18年。她也是GeneCentric療法的創始人和主席,她先前總裁兼首席執行官。此外,她是一個風險Hatteras venture Partners的合夥人和個性化的管理合夥人科學,一個診斷谘詢公司。Quantum-Si:凱瑟琳·阿特金森,亞曆克斯·哈奇森拉他,約翰Vieceli Quantum-Si多次新任命的領導團隊,命名凱瑟琳·阿特金森作為需求生成和公司品牌的高級副總裁,亞曆克斯·哈奇森作為銷售和服務的高級副總裁,克裏斯汀西山製造業供應鏈副總裁和試劑,和約翰Vieceli算法和數據科學的副總裁。阿特金森以前首席商務官Evofem生物科學和之前在Truvian擔任領導職位,史詩,Edico基因組,Illumina公司。Hutcheson以前的銷售副總裁,北美,Inscripta和之前的角色在太平洋生物科學,Genetix Biacore,貝克曼庫爾特。他以前操作在牛津Nanoimaging和副總裁也在伯克利舉行燈,和或技術、濱鬆光子學,雷神公司。Vieceli以前高級生物信息學主要研究員Illumina公司並擔任領導職位Omniome和太平洋生物科學。Nonagen生物科學:蒂莫西·約翰遜Nonagen生物科學已任命約翰遜蓋“TJ”執行主席。 Johnson has held C-suite and executive-level leadership positions for several life sciences companies, including Ventana Medical Systems, which was acquired by Roche in 2007. He spent more than 12 years as president and CEO and as a member of the board of directors at HTG Molecular Diagnostics. Previously, he spent more than 10 years at Hillenbrand Industries. Johnson holds a bachelor's degree in business from Indiana University. Circular Genomics: Paul Sargeant Circular Genomics, an Albuquerque, New Mexico-based company developing precision medicine and diagnostic tools based on circular RNA, has appointed Paul Sargeant as CEO. Sargeant has more than 25 years of life science industry leadership and management experience including clinical diagnostics assay, instrumentation platform, and software development; regulatory approvals; and commercial launch experience, according to Circular. Most recently, Sargeant was CEO of Rebus Biosystems, an Illumina Ventures-backed spatial biology company. He holds a PhD in physiology from the University of Cambridge. Foresight Diagnostics: Uplaksh Kumar Uplaksh Kumar will be joining Foresight Diagnostics' board of directors in conjunction with the firm's recent Series B financing round. Kumar is a venture partner at Foresite Capital, the lead investor in the round. Previously, he was senior VP of strategic operations and scale at Grail. Prior to that, he was head of operations at Verily and held various leadership positions at Life Technologies, BD, Lonza, and Qiagen. Acuamark Diagnostics: Giulia Kennedy Cancer testing firm Acuamark Diagnostics has appointed Giulia Kennedy to its board of directors. She is former CSO and chief medical officer of cancer genetics company Veracyte. Prior to that, she was with Affymetrix. William Gedale, executive chairman of New York City-based Acuamark, said in a statement that Kennedy's diverse experience in diagnostics and expertise in attracting capital and driving commercial development are essential to this phase of Acuamark's growth. For additional recent items on executive appointments, promotions, and departures in the omics and molecular diagnostics space, please see the People in the News page on our website.